



The Syngene logo is displayed in a white, italicized sans-serif font against a dark blue background.

Putting Science to Work

Small Molecule Drug Substance Development & Manufacturing

A microscopic image showing a cross-section of a cell or tissue. It features a bright orange, granular outer layer and several blue, circular structures with internal detail, possibly representing nuclei or organelles.

Science
For People
**ADVANCING
INNOVATION**

A photograph of an industrial pharmaceutical manufacturing process. Several vertical robotic arms are shown, each with a small, clear glass vial at the bottom. The vials are being filled with a clear liquid. The background is a deep blue, and the lighting is focused on the vials and the mechanical components of the machinery.

From First Route to
Commercial Supply,
Without Compromise

Small Molecule Drug Substance Development & Manufacturing

Syngene's small molecule drug substance development and manufacturing services are powered by a multidisciplinary team and robust infrastructure supporting a wide range of molecules including oligonucleotides, peptides, polymers, and HPAPIs.



Team of 1150+ professionals including scientists, engineers, QA/QC, regulatory, SCM, and PM



Facilities for both GMP and non-GMP operations.



Proven track record: 250+ route scouting projects, 200+ process developments, and over 300 MT of material delivered



Over 2700 analytical methods developed, 5 joint patents filed, and 4 products successfully commercialized

Process Research and Development

To support scalable and robust manufacturing, Syngene's Process Research and Development (PRD) capabilities include complex organic synthesis, flow chemistry, and advanced purification systems.

- Expertise in heterocycles, natural products, peptides, oligonucleotides, and ADC payloads
- Advanced tools: automated jacketed reactors, parallel synthesizers, PAT tools (FBRM, PVM, React-IR)
- Photochemical and cryogenic reactor setups for sensitive reactions

Analytical and Process Safety

Syngene provides comprehensive analytical development and rigorous process safety protocols to ensure quality and compliance throughout the development lifecycle.

- Extensive analytical capabilities: LC-MS, GC-MS, NMR, SFC, Prep HPLC
- Services include method development, impurity profiling, and ICH stability studies
- Process safety tools: calorimetry (DSC, ARC), gas quantification, powder safety assessments
- CCPS-based safety protocols implemented across all laboratories

Engineering and Commercial Scale-Up

Syngene's engineering team ensures seamless scale-up to commercial manufacturing through detailed studies and simulation tools, supporting commercial viability of complex processes.



In-depth studies covering corrosion, mixing, distillation, filtration, and drying



Process simulation using Dynochem and Design Expert



Flow chemistry platforms including Vapourtec and H-Cube for continuous manufacturing



Demonstrated success in kilogram-scale production using metal carbanion chemistry

Manufacturing Infrastructure and Certifications

Syngene's manufacturing facilities in Bangalore and Mangalore support kilo to commercial-scale production with global regulatory approvals.

Bangalore (B-SEZ) & Mangalore (M-SEZ)

Mfg. Facility	Bangalore (B-SEZ)				Mangalore (M-SEZ)
	S1 Kilo Lab (GMP)	U-2 Kilo Lab (non-GMP)	HPAPI GMP (OEB-4 & 5) USFDA, PMDA	S14 Semi-commercial GMP USFDA, PMDA	Mangalore Including high potent Intermediate Block Commercial GMP USFDA (OEB-4)
Range	10-20 L	10-50 L	60 L to 630 L	60 L to 8000 L	1000 L to 12,500 L
Total Capacity	120 L	90 L	2010 L	63,600 L	71,000 L
Largest Reactor	20 L	50 L	630 L	8000 L	12,500 L
Reactors	3	4	5	32	12
Total number of reactors (Manufacturing Volumes)				56 reactors (~135,000 L) & expanding SEZ = Special Economic Zone	

- Combined reactor volume: ~135,000 liters across 56 reactors
- Reactor range: 10 L to 12,500 L across GMP and non-GMP blocks
- Certifications: USFDA, PMDA, EMA, ANVISA, GLP, AAALAC, CAP, and Russian Ministry of Health
- 15+ regulatory audits and 160+ client audits completed in last 3 years






Development & Manufacturing for Specialized Modalities

Syngene offers advanced capabilities in cryogenic chemistry, peptide synthesis, oligonucleotide manufacturing, and ADC development

- Cryogenic reactions down to -110°C for sensitive intermediates
- Peptide synthesis: Over 1000 peptides delivered, up to 65-mer
- Oligonucleotide expertise for therapeutic, diagnostic, and homopolymer oligos
- End-to-end ADC services: linker-payload synthesis, DAR analysis, stability, PK, and tox studies

Seamless Technology Transfer for Manufacturing Success

Syngene ensures seamless technology transfer from PRD and ARD at BSEZ to manufacturing at MSEZ through structured workflows and cross-functional collaboration.



Green Chemistry and Sustainability

Syngene integrates green chemistry principles to reduce environmental impact and improve process efficiency

- Extensive analytical capabilities: LC-MS, GC-MS, NMR, SFC, Prep HPLC
- Services include method development, impurity profiling, and ICH stability studies
- Process safety tools: calorimetry (DSC, ARC), gas quantification, powder safety assessments
- CCPS-based safety protocols implemented across all laboratories



Success in Scaling and Commercialization

Syngene's success stories demonstrate its ability to deliver complex programs with speed, quality, and regulatory compliance

- **Case Study 1:** Syngene partnered with a global pharmaceutical company to support development from early-stage research to commercial launch. Delivered multiple batches ranging from 5 kg to 24 kg, supporting clinical trials and regulatory submissions
- **Case Study 2:** In collaboration with a Japanese pharmaceutical company, Syngene scaled up production from 100 grams to over 1000 kilograms. The PMDA-approved Bangalore facility enabled successful execution of clinical and commercial campaigns

Partner with A Leader in Drug Substance Manufacturing

Syngene combines deep scientific expertise, advanced infrastructure, and a proven track record of regulatory compliance to deliver reliable chemical development solutions. From low-temperature cryogenic reactions to high-potency API manufacturing, our capabilities are designed to help clients overcome complex challenges with confidence. With a commitment to quality, safety, and innovation, we accelerate the development and delivery of tomorrow's medicines, making Syngene a trusted partner for pharmaceutical and biotech companies worldwide.

Notes

Notes

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated CRDMO (Contract Research, Development and Manufacturing Organization), serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's ~6000 scientists bring the skills and capacity to deliver great science, strong data security, and quality manufacturing, at speed, helping improve time-to-market and lower the cost of innovation. This is backed by ring-fenced dedicated centers, as well as ~3 Mn sq. ft. of specialist discovery, development, and manufacturing facilities.

For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com